ArticleAmerican journal of translational research2022
Integrative analysis of CBR1 as a prognostic factor associated with IDH-mutant glioblastoma in the Chinese population.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Robust Cluster Prediction Across Data Types Validates Association of Sex and Therapy Response in GBM.Cancers · 2025Article
- Single cell sequencing revealed the mechanism of CRYAB in glioma and its diagnostic and prognostic value.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is a common primary intracranial tumor with poor prognosis. Common indicators in the clinical diagnosis of glioma include MGMT promoter methylation, isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion, and TERT mutation. Among these, IDH mutation is extremely important for GBM diagnosis and treatment.
methodsThe Chinese Glioma Population Database (CGGA) and Gene Expression Omnibus (GEO) data (GSE131273) related to glioma in the Chinese population were used for differential analysis (DGA) and weighted gene coexpression network analysis (WGCNA). The expression levels of hub genes between the IDH1 wild-type and mutant GBM cell lines were detected by RT-qPCR. Kaplan-Meier (KM) plotter was used to analyze hub gene expression levels and prognostic values.
resultsEight hub genes were identified by WGCNA and different expression genes (DEG) analysis, namely, one upregulated gene (CRYAB) and seven downregulated genes (EFEMP2, RBP1, TAGLN2, CBR1, MSN, ALDH7A1, and MT1M). Four of these genes (ALDH7A1, MSN, CBR1, and MTM1) showed significant differences between IDH-wild-type and IDH-mutant GBM, verified at the cellular level. Moreover, the high expression of CBR1 was significantly correlated with poor overall survival (OS) in patients with IDH-mutant GBM, and we finally identified CBR1 as a specific prognostic factor in IDH-mutant GBM.
conclusionResults revealed different gene expressions between IDH-wild-type and IDH-mutant GBM. These genes may help monitor the occurrence and development of glioma. CBR1 can be used as a prognostic marker to identify IDH-mutant glioblastoma patients.
Indexed as
Identifiers
36105052PMC9452365W4295898636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.